Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Syros Pharmaceuticals, Inc. (SYRS)
|
Add to portfolio |
|
|
|
| Price: |
$6.32
| | Metrics |
| OS: |
20.7
|
M
| |
|
|
| Market cap: |
$131
|
M
| |
|
|
|
Net cash:
|
$115
|
M
| |
$5.57
|
per share
|
|
EV:
|
$15.4
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 14.9 | 23.5 | 15.1 | 2.0 | 4.2 | 1.1 | 0.3 | 0.3 |
| Revenue growth | -36.6% | 55.6% | 661.5% | -52.2% | 276.9% | 247.3% | 0.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 | 0.0 | 0.0 | 0.0 |
| Gross profit | 14.9 | 23.5 | 15.1 | 2.0 | 2.1 | 1.1 | 0.3 | 0.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 49.4% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 150.8 | 122.9 | 97.4 | | | | | |
| Research and development | | | | 58.2 | 50.2 | 41.9 | 37.8 | 24.4 |
| General and administrative | | | | 21.5 | 16.2 | 13.9 | 10.5 | 5.7 |
| EBIT | -137.9 | -103.2 | -83.7 | -77.7 | -64.3 | -54.7 | -48.0 | -29.8 |
| EBIT margin | -926.6% | -439.5% | -554.3% | -3922.4% | -1549.3% | -4966.9% | -15130.3% | -9406.9% |
| Pre-tax income | -94.7 | -86.6 | -84.0 | -75.4 | -62.3 | -54.0 | -47.7 | -29.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | | | 0.0% | 0.0% |
| Net income | -94.7 | -86.6 | -84.0 | -75.4 | -62.3 | -54.0 | -51.4 | -34.8 |
| Net margin | -636.1% | -368.5% | -556.8% | -3806.2% | -1500.7% | -4905.5% | -16222.1% | -10962.8% |
| |
| Diluted EPS | ($7.49) | ($13.84) | ($18.25) | ($1.88) | ($1.91) | ($2.13) | ($4.05) | ($17.55) |
| Shares outstanding (diluted) | 12.6 | 6.3 | 4.6 | 40.2 | 32.7 | 25.4 | 12.7 | 2.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|